Global Hemoglobinopathies Treatment Market 2019-2023

異常ヘモグロビン症の世界市場2019-2023

◆タイトル:Global Hemoglobinopathies Treatment Market 2019-2023
◆商品コード:IRTNTR30546
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年12月28日
◆ページ数:113
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、異常ヘモグロビン症の世界市場について調査・分析し、市場概要、市場環境、異常ヘモグロビン症市場規模、種類別(鎌状赤血球症、サラセミア)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・異常ヘモグロビン症の世界市場概要
・異常ヘモグロビン症の世界市場環境
・異常ヘモグロビン症の世界市場動向
・異常ヘモグロビン症の世界市場規模
・異常ヘモグロビン症の世界市場:業界構造分析
・異常ヘモグロビン症の世界市場:種類別(鎌状赤血球症、サラセミア)
・異常ヘモグロビン症の世界市場:地域別市場規模・分析
・異常ヘモグロビン症の北米市場規模・予測
・異常ヘモグロビン症のヨーロッパ・中東・アフリカ市場規模・予測
・異常ヘモグロビン症のアジア太平洋市場規模・予測
・異常ヘモグロビン症の主要国分析
・異常ヘモグロビン症の世界市場:意思決定フレームワーク
・異常ヘモグロビン症の世界市場:成長要因、課題
・異常ヘモグロビン症の世界市場:競争環境
・異常ヘモグロビン症の世界市場:関連企業情報(ベンダー分析)

About this market
Development of gene therapy to drive growth in the market. The advances of regenerative medicines in the clinical phases are expected to fuel growth of the global hemoglobinopathies treatment market. Technavio’s analysts have predicted that the hemoglobinopathies treatment market will register a CAGR of almost 11% by 2023.
Market Overview
Strong pipeline and expected approvals of late-stage molecule
The market is witnessing an acute lack of approved therapies, these late-stage pipeline molecules are expected to gain momentum during the forecast period, which will fuel the market growth.
Product recalls and tedious drug approval process
The strict regulations for providing the marketing approval for therapeutics that are being developed for the treatment of hemoglobinopathies is likely to pose a threat to the market.
For the detailed list of factors that will drive and challenge the growth of the hemoglobinopathies treatment market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Medunik USA and Novartis the competitive environment is quite intense. Factors such as the strong pipeline and expected approvals of late-stage molecule and the development of gene therapy, will provide considerable growth opportunities to hemoglobinopathies treatment manufactures. ApoPharma, Bristol-Myers Squibb, Emmaus Medical, Medunik USA, and Novartis are some of the major companies covered in this report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Sickle cell disease – Market size and forecast 2018-2023
• Thalassemia – Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
PART 10: VENDOR LANDSCAPE
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ApoPharma
• Bristol-Myers Squibb
• Emmaus Medical
• Medunik USA
• Novartis
PART 14: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global hematology drugs market
Exhibit 03: Segments of global hematology drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Sickle cell disease – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Sickle cell disease – Year-over-year growth 2019-2023 (%)
Exhibit 22: Thalassemia – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Thalassemia – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Therapeutics that have received the orphan drug designation from the US FDA recently
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: ApoPharma – Vendor overview
Exhibit 48: ApoPharma – Business segments
Exhibit 49: ApoPharma – Organizational developments
Exhibit 50: ApoPharma – Key offerings
Exhibit 51: ApoPharma – Key customers
Exhibit 52: Bristol-Myers Squibb – Vendor overview
Exhibit 53: Bristol-Myers Squibb – Business segments
Exhibit 54: Bristol-Myers Squibb – Organizational developments
Exhibit 55: Bristol-Myers Squibb – Geographic focus
Exhibit 56: Bristol-Myers Squibb – Key offerings
Exhibit 57: Bristol-Myers Squibb – Key customers
Exhibit 58: Emmaus Medical – Vendor overview
Exhibit 59: Emmaus Medical – Business segments
Exhibit 60: Emmaus Medical – Organizational developments
Exhibit 61: Emmaus Medical – Geographic focus
Exhibit 62: Emmaus Medical – Key offerings
Exhibit 63: Emmaus Medical – Key customers
Exhibit 64: Medunik USA – Vendor overview
Exhibit 65: Medunik USA – Business segments
Exhibit 66: Medunik USA – Organizational developments
Exhibit 67: Medunik USA – Key offerings
Exhibit 68: Medunik USA – Key customers
Exhibit 69: Novartis – Vendor overview
Exhibit 70: Novartis – Business segments
Exhibit 71: Novartis – Organizational developments
Exhibit 72: Novartis – Geographic focus
Exhibit 73: Novartis – Segment focus
Exhibit 74: Novartis – Key offerings
Exhibit 75: Novartis – Key customers
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: List of abbreviations



【掲載企業】

ApoPharma
Bristol-Myers Squibb
Emmaus Medical
Medunik USA
Novartis

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[異常ヘモグロビン症の世界市場2019-2023]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆